Dmitri Sviridov

List of Publications by Year
in descending order

88	4,395	117453	110170
papers	citations	34 h-index	64 g-index

90	90	90	4920
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Abundance of Nef and p-Tau217 in Brains of Individuals Diagnosed with HIV-Associated Neurocognitive Disorders Correlate with Disease Severance. Molecular Neurobiology, 2022, 59, 1088-1097.	1.9	7
2	Specific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis. Diabetes, 2021, 70, 772-787.	0.3	84
3	Non-linear optical imaging of atherosclerotic plaques in the context of SIV and HIV infection prominently detects crystalline cholesterol esters. PLoS ONE, 2021, 16, e0251599.	1.1	2
4	Direct interaction between ABCA1 and HIV-1 Nef: Molecular modeling and virtual screening for inhibitors. Computational and Structural Biotechnology Journal, 2021, 19, 3876-3884.	1.9	5
5	Biology of Lipid Rafts: Introduction to the Thematic Review Series. Journal of Lipid Research, 2020, 61, 598-600.	2.0	14
6	Lipid rafts and pathogens: the art of deception and exploitation. Journal of Lipid Research, 2020, 61, 601-610.	2.0	43
7	Comorbidities of HIV infection. Aids, 2020, 34, 1-13.	1.0	30
8	Modification of lipid rafts by extracellular vesicles carrying HIV-1 protein Nef induces redistribution of amyloid precursor protein and Tau, causing neuronal dysfunction. Journal of Biological Chemistry, 2020, 295, 13377-13392.	1.6	20
9	Targeting Lipid Raftsâ€"A Potential Therapy for COVID-19. Frontiers in Immunology, 2020, 11, 574508.	2.2	45
10	Cholesterol transport between red blood cells and lipoproteins contributes to cholesterol metabolism in blood. Journal of Lipid Research, 2020, 61, 1577-1588.	2.0	15
11	Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. PLoS ONE, 2020, 15, e0237739.	1.1	10
12	Cholesterol Efflux-Independent Modification of Lipid Rafts by AIBP (Apolipoprotein A-I Binding) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302	1.1	11
13	Lipid rafts as a therapeutic target. Journal of Lipid Research, 2020, 61, 687-695.	2.0	72
14	ABCA12 regulates insulin secretion from Î²â€cells. EMBO Reports, 2020, 21, e48692.	2.0	13
15	Inhibition of HIV Replication by Apolipoprotein A-I Binding Protein Targeting the Lipid Rafts. MBio, 2020, 11, .	1.8	24
16	Isolation of Lipid Rafts from Cultured Mammalian Cells and Their Lipidomics Analysis. Bio-protocol, 2020, 10, e3670.	0.2	4
17	Exosomes containing HIV protein Nef reorganize lipid rafts potentiating inflammatory response in bystander cells. PLoS Pathogens, 2019, 15, e1007907.	2.1	86
18	HIV disease, metabolic dysfunction and atherosclerosis: A three year prospective study. PLoS ONE, 2019, 14, e0215620.	1.1	20

#	Article	IF	Citations
19	Cdc42 â€“ A tryst between host cholesterol metabolism and infection. Small GTPases, 2018, 9, 237-241.	0.7	4
20	Inhibition of Neuroinflammation by AIBP: Spinal Effects upon Facilitated Pain States. Cell Reports, 2018, 23, 2667-2677.	2.9	51
21	Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. Bioscience Reports, 2018, 38, .	1.1	6
22	Apolipoprotein A-I Mimetic Peptides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1301-1306.	1.1	21
23	Short Communication: Accumulation of Neutral Lipids in Liver and Aorta of Nef-Transgenic Mice. AIDS Research and Human Retroviruses, 2017, 33, 57-60.	0.5	8
24	Interaction Between HIV-1 Nef and Calnexin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1758-1771.	1.1	21
25	Cytomegalovirus Restructures Lipid Rafts via a US28/CDC42-Mediated Pathway, Enhancing Cholesterol Efflux from Host Cells. Cell Reports, 2016, 16, 186-200.	2.9	39
26	Small GTPase ARF6 Regulates Endocytic Pathway Leading to Degradation of ATP-Binding Cassette Transporter A1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2292-2303.	1.1	31
27	Lipidomic dataset of plasma from patients infected with wild type and nef-deficient HIV-1 strain. Data in Brief, 2016, 6, 168-175.	0.5	1
28	Lipid metabolism in patients infected with Nef-deficient HIV-1 strain. Atherosclerosis, 2016, 244, 22-28.	0.4	16
29	Analysis of ABCA1 and Cholesterol Efflux in HIV-Infected Cells. Methods in Molecular Biology, 2016, 1354, 281-292.	0.4	5
30	Inhibition of Extracellular Cyclophilins with Cyclosporine Analog and Development of Atherosclerosis in Apolipoprotein Eâ€“Deficient Mice. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 490-495.	1.3	9
31	High-density lipoprotein mimetics: promises and challenges. Biochemical Journal, 2015, 472, 249-259.	1.7	25
32	Fetal inhibition of inflammation improves disease phenotypes in harlequin ichthyosis. Human Molecular Genetics, 2015, 24, 436-449.	1.4	17
33	Stimulation of Liver X Receptor Has Potent Anti-HIV Effects in a Humanized Mouse Model of HIV Infection. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 376-383.	1.3	14
34	HIV infection induces structural and functional changes in high density lipoproteins. Atherosclerosis, 2015, 243, 19-29.	0.4	27
35	High-Density Lipoprotein Ã¢â‚¬â€œ A Hero, a Mirage, or a Witness?. Frontiers in Cardiovascular Medicine, 2014, 1, 9.	1.1	3
36	HIV-1 Protein Nef Inhibits Activity of ATP-binding Cassette Transporter A1 by Targeting Endoplasmic Reticulum Chaperone Calnexin. Journal of Biological Chemistry, 2014, 289, 28870-28884.	1.6	30

#	Article	IF	Citations
37	HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis. FASEB Journal, 2014, 28, 2828-2839.	0.2	45
38	Interaction of pathogens with host cholesterol metabolism. Current Opinion in Lipidology, 2014, 25, 333-338.	1.2	40
39	Prion Infection Impairs Cholesterol Metabolism in Neuronal Cells. Journal of Biological Chemistry, 2014, 289, 789-802.	1.6	31
40	ABCA12 Regulates ABCA1-Dependent Cholesterol Efflux from Macrophages and the Development of Atherosclerosis. Cell Metabolism, 2013, 18, 225-238.	7.2	46
41	The effect of HIV infection on atherosclerosis and lipoprotein metabolism: A one year prospective study. Atherosclerosis, 2013, 229, 206-211.	0.4	31
42	Anti-Inflammatory Functions of Apolipoprotein A-I and High-Density Lipoprotein Are Preserved in Trimeric Apolipoprotein A-I. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 41-49.	1.3	21
43	An Apolipoprotein A-I Mimetic Peptide Designed with a Reductionist Approach Stimulates Reverse Cholesterol Transport and Reduces Atherosclerosis in Mice. PLoS ONE, 2013, 8, e68802.	1.1	28
44	Cyclophilins in Atherosclerosis: A New Therapeutic Target?. Current Pharmaceutical Design, 2013, 19, 5904-5908.	0.9	4
45	Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. European Heart Journal, 2012, 33, 657-665.	1.0	60
46	Cholesterol Efflux Assay. Journal of Visualized Experiments, 2012, , e3810.	0.2	74
47	HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux. Journal of Lipid Research, 2012, 53, 696-708.	2.0	69
48	Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection. Biochemical and Biophysical Research Communications, 2012, 419, 95-98.	1.0	19
49	Global functional knockdown of ATP binding cassette transporter A1 stimulates development of atherosclerosis in apoE K/O mice. Biochemical and Biophysical Research Communications, 2011, 412, 446-449.	1.0	4
50	Fenofibrate, homocysteine, cholesterol efflux and primum non nocere. Atherosclerosis, 2011, 219, 24-25.	0.4	1
51	Neutrophil Activation Is Attenuated by High-Density Lipoprotein and Apolipoprotein A-I in In Vitro and In Vivo Models of Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1333-1341.	1.1	172
52	Structure/Function Relationships of Apolipoprotein A-I Mimetic Peptides. Circulation Research, 2010, 107, 217-227.	2.0	71
53	5A Apolipoprotein Mimetic Peptide Promotes Cholesterol Efflux and Reduces Atherosclerosis in Mice. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 634-641.	1.3	103
54	Introduction. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 700-702.	0.9	1

#	Article	IF	Citations
55	Circulating Nef Induces Dyslipidemia in Simian Immunodeficiency Virusâ€“Infected Macaques by Suppressing Cholesterol Efflux. Journal of Infectious Diseases, 2010, 202, 614-623.	1.9	51
56	High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus. Circulation, 2009, 119, 2103-2111.	1.6	363
57	Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux. Circulation, 2009, 120, 2095-2104.	1.6	167
58	Maturation of apolipoprotein A-I: unrecognized health benefit or a forgotten rudiment?. Journal of Lipid Research, 2009, 50, 1257-1258.	2.0	7
59	Impact of freezing on high-density lipoprotein functionality. Analytical Biochemistry, 2008, 379, 213-215.	1.1	15
60	Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis, 2008, 197, 732-739.	0.4	42
61	HIV infection and high density lipoprotein metabolism. Atherosclerosis, 2008, 199, 79-86.	0.4	127
62	Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque. Circulation Research, 2008, 103, 1084-1091.	2.0	251
63	Asymmetry in the Lipid Affinity of Bihelical Amphipathic Peptides. Journal of Biological Chemistry, 2008, 283, 32273-32282.	1.6	87
64	Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo. Journal of Lipid Research, 2008, 49, 2312-2322.	2.0	44
65	A Mouse Model of Harlequin Ichthyosis Delineates a Key Role for Abca12 in Lipid Homeostasis. PLoS Genetics, 2008, 4, e1000192.	1.5	70
66	High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2071-2077.	1.1	392
67	The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovascular Research, 2008, 77, 732-739.	1.8	68
68	Antiatherogenic Functionality of High Density Lipoprotein: How Much versus How Gooden-subtitle=. Journal of Atherosclerosis and Thrombosis, 2008, 15, 52-62.	0.9	100
69	HIV and Cardiovascular Disease: Contribution of HIV-Infected Macrophages to Development of Atherosclerosis. PLoS Medicine, 2007, 4, e43.	3.9	18
70	Statins and Metabolism of High Density Lipoprotein. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2007, 5, 215-221.	0.4	20
71	The Role of Different Regions of ATP-Binding Cassette Transporter A1 in Cholesterol Efflux. Biochemistry, 2007, 46, 9388-9398.	1.2	22
72	HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism: Clinical and Experimental, 2006, 55, 90-95.	1.5	88

#	Article	IF	Citations
73	Elevated HDL Cholesterol is Functionally Ineffective in Cardiac Transplant Recipients: Evidence for Impaired Reverse Cholesterol Transport. Transplantation, 2006, 81, 361-366.	0.5	28
74	Human Immunodeficiency Virus Impairs Reverse Cholesterol Transport from Macrophages. PLoS Biology, 2006, 4, e365.	2.6	266
75	Expression of Caveolin-1 Enhances Cholesterol Efflux in Hepatic Cells. Journal of Biological Chemistry, 2004, 279, 14140-14146.	1.6	93
76	Natural mutations of apolipoprotein A-I impairing activation of lecithin:cholesterol acyltransferase. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1631, 72-76.	1.2	10
77	Single session exercise stimulates formation of preÎ²1-HDL in leg muscle. Journal of Lipid Research, 2003, 44, 522-526.	2.0	28
78	Low-Density Lipoprotein Receptor and Apolipoprotein A-I and B Expression in Human Enterocytes. Digestion, 2003, 67, 67-70.	1.2	6
79	Delineation of the Role of Pre-Î²1-HDL in Cholesterol Efflux Using Isolated Pre-Î²1-HDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1482-1488.	1.1	31
80	Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis, 2002, 161, 245-254.	0.4	135
81	Characterization of the Maturation of Human Pro-apolipoprotein A-I in an in Vitro Model. Biochemistry, 2001, 40, 3101-3108.	1.2	9
82	Apolipoprotein A-I stimulates the transport of intracellular cholesterol to cell-surface cholesterol-rich domains (caveolae). Biochemical Journal, 2001, 358, 79.	1.7	29
83	Apolipoprotein A-I stimulates the transport of intracellular cholesterol to cell-surface cholesterol-rich domains (caveolae). Biochemical Journal, 2001, 358, 79-86.	1.7	41
84	Identification of a Sequence of Apolipoprotein A-I Associated with the Activation of Lecithin:Cholesterol Acyltransferase. Journal of Biological Chemistry, 2000, 275, 19707-19712.	1.6	41
85	Effectivity of Expression of Mature Forms of Mutant Human Apolipoprotein A-I. Protein Expression and Purification, 1999, 17, 231-238.	0.6	8
86	Production of Mature Human Apolipoprotein A-I in a Baculovirusâ€“Insect Cell System: Propeptide Is Not Essential for Intracellular Processing but May Assist Rapid Secretion. Analytical Biochemistry, 1997, 253, 253-258.	1.1	18
87	Efflux of Cellular Cholesterol and Phospholipid to Apolipoprotein A-I Mutants. Journal of Biological Chemistry, 1996, 271, 33277-33283.	1.6	61
88	Trained Immunity and HIV Infection. Frontiers in Immunology, 0, 13, .	2.2	6